Biotech rNPV and sum-of-the-parts model
Value a development-stage biotech programme by programme: build a launch curve from patients and price, risk-adjust by stage, discount to an rNPV, and sum the parts to a price per share.
Healthcare companies are valued in two very different ways, depending on whether their products have reached the market. A development-stage biotech is worth the probability-weighted value of drugs that may never be approved, so it is modelled programme by programme: patients and price after launch, risk-adjusted by the chance of clearing every stage still ahead, and moved by binary events such as a trial readout. A medtech company with products on the market is worth what its installed base earns: systems placed, procedures performed on each, and the instruments, service and lease payments every procedure pulls through. A hospital operator sells care rather than a product: its volume comes from beds, occupancy and length of stay, its price from who pays for the patient, and its margin from the staff it takes to run the beds. A royalty holder owns neither the drug nor the costs of making it: it is paid a tiered share of another company’s sales and the milestones in the licence, so it is valued on the licensee’s sales curve, the royalty term and the probability that a pipeline product is approved.
By Surojit Chakraverti, founder of L3VLUP and an investor running a long-short healthcare and technology equities strategy.
On this subject: healthcare.Updated 5 November 2026
Value a development-stage biotech programme by programme: build a launch curve from patients and price, risk-adjust by stage, discount to an rNPV, and sum the parts to a price per share.
Roll an installed base of sold and leased systems, drive procedures and consumables from utilisation, separate recurring from capital revenue, account for leased systems as capital, and decide whether a system is worth more sold or leased.
Build a hospital operator from its beds: patient days, admissions and adjusted admissions, revenue by payer with price concessions on self-pay, labour from staffing ratios and contract labour, supplies, EBITDA, then free cash flow, a buyout’s debt and the sponsor’s return, and read what a payer mix shift or a labour shock does to each.
Value a portfolio of drug royalties from the licensee’s sales: build each product’s sales curve to generic entry, apply the licence’s tiered rates band by band, end the royalty at patent expiry, weight development products by their probability of approval, collect with the lag, and price a new royalty purchase on its IRR.
Other areas: Core modelling · M&A and private equity · Credit and restructuring · Real estate · Infrastructure and project finance · Technology · Financial institutions · All 57 models
Start with the biotech readout lab, which values a company on either side of its next trial and reads the probability of success off the share price. Then open the biotech rNPV model to see the same values built from patients, prices and stage probabilities for three programmes. The medtech model is the other half of the sector: change utilisation or the share of systems leased and watch recurring revenue, margins and free cash flow move. The hospital operator model is healthcare services: switch to the payer mix shift or the labour shock and watch revenue per adjusted admission, the EBITDA margin, leverage and a buyer’s return move. The pharma royalty model sees a drug from the other side of the licence: switch to earlier generic entry or pipeline failure and watch the portfolio’s value and the return on a royalty purchase move. Each model has a starter workbook that leaves one schedule for you to build.
Each schedule is one reusable calculation, explained on its own page with the rows it occupies in every model that uses it.
Healthcare schedules
Clinical probability and stage gating
The chance of reaching the market, and what it weights
Healthcare schedules
Launch curve
Patients times price, ramped to peak, eroded at exclusivity loss
Healthcare schedules
Programme rNPV
Revenue to risk-adjusted cash flow to a value
Healthcare schedules
Sum of the parts
Programmes, corporate costs, net cash, per share
Healthcare schedules
Binary events: the Phase 3 readout
Value on success, value on failure, the implied probability
Healthcare schedules
Installed base and utilisation
Systems shipped, retired and in use, and procedures
Healthcare schedules
Consumables pull-through and recurring revenue
Instruments per procedure, service, leases, margins
Operating schedules
Capex and depreciation (PP&E roll-forward)
Opening, plus capex, less depreciation, closing
Operating schedules
Working capital schedule
Receivables, inventory and payables in days
Healthcare schedules
Placement economics: sell or lease
Lifetime value of a system sold or leased, payback
Healthcare schedules
Hospital volumes and adjusted admissions
Beds, occupancy, length of stay, adjusted admissions
Healthcare schedules
Payer mix and hospital revenue
Revenue by payer, self-pay concessions, net revenue
Healthcare schedules
Hospital labour, supplies and EBITDA
FTEs per bed, wage inflation, contract labour, supplies
Transaction schedules
Sources and uses
What the deal costs and who funds it
Financing schedules
Debt schedule
Tranches, interest, amortisation and the sweep
Valuation and returns
Returns analysis
Exit value, MOIC, IRR and the bridge
Valuation and returns
Sensitivity tables
Two assumptions at once, without a data table
Healthcare schedules
Royalty receipts and milestones
Sales curve, milestones, collection lag, operating costs
Healthcare schedules
Tiered royalty rates
Sales bands, marginal rates, step-down, royalty term
Healthcare schedules
Royalty purchase returns
Price, receipts, IRR, multiple and the highest price
Biotech Readout · 12 min
Multiply stage probabilities, risk-adjust a programme, value a company in each outcome with a cash floor, and read the implied probability of success off a share price.
Paper LBO Trainer · 8 min
Solve MOIC and IRR in your head from a deal you have never seen, in under ten minutes.
Depreciation Waterfall · 10 min
Forecast depreciation from a capex plan rather than a ratio, read a capex-to-depreciation multiple, and say which part of the spend is buying growth and which is only standing still.
Three-Statement Linker · 8 min
Walk any event through all three statements in the right order, with the right signs, and prove the balance sheet balances rather than asserting it.
LBO Modelling Test · 60 min
Sit the one-hour test under a clock, in the browser or in your own workbook, and get every line of the build marked.
Capital Stack Challenge · 15 min
Finance a real buyout from revolver to equity, hold it through a shock, and explain every layer against the deal the sponsor actually did.
Optimal Capital Structure · 15 min
Explain why more debt stops helping: watch coverage, rating and spread move as leverage rises until WACC turns.
IRR by Eye · 3 min
Say the IRR for any multiple and hold before the interviewer finishes the sentence, and the multiple for any IRR.
Napkin LBO · 12 min
Sketch a full buyout by hand, from sources and uses through the debt paydown to the return, and say which bucket the return depends on.
DCF Builder · 15 min
Build a DCF by hand from revenue to a share price, know how much of it sits in the terminal value, and name the one assumption the answer hinges on.
Cover a sector, publish a view, defend it to clients. The best writing training on the map.
How to get in and prepareLong/short equity, credit, macro or multi-strategy. A view, sized, with a stop.
How to get in and prepareAdvise on M&A and capital raising. The training ground the rest of the map feeds off.
How to get in and prepareEarly-stage minority investing. Judgement about people and markets, far less modelling.
How to get in and prepareBuy control of established companies using debt, improve them, sell them.
How to get in and prepareA biotech with no approved product is valued on probability: each programme’s cash flows after launch are weighted by the chance of reaching the market, which is why its value jumps or collapses on a trial result. A medtech company with products on the market is valued on its installed base and how hard each system is worked, so it is modelled more like a recurring-revenue business than a pipeline.
For biotech: rNPV, stage probabilities of success, peak sales, loss of exclusivity and how to value a binary event. For medtech: installed base, utilisation, the razor-and-blade split between capital and recurring revenue, and leasing against selling. The biotech readout lab drills the first set, and each model page lists the mistakes a reviewer looks for.
Because it is earned on every procedure for the life of every installed system, so it grows with the base and is far more predictable than system sales, which depend on hospital capital budgets. Investors pay a higher multiple for it, and a company that shifts towards leasing raises its recurring share at the cost of revenue and cash today.
From its beds. Beds, occupancy and the average length of stay give admissions; outpatient visits join them as adjusted admissions; each payer’s share and rate give revenue, with self-pay charges reduced by price concessions; staffing ratios and wage inflation give labour, the largest cost. Interviews test adjusted admissions, payer mix and why a labour shortage compresses margins when prices are set by payers.
From the licensee’s sales. Each product’s sales curve runs from launch to peak and falls when generics arrive; the licence’s tiered rates are applied band by band to each year’s sales until the royalty term ends; development products are weighted by their probability of approval; and the receipts, with any milestones, are discounted. A buyer prices a royalty on the IRR those receipts earn at the price asked.